{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MLN9708&page=2", "query": { "intervention": "MLN9708", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MLN9708&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-19T01:22:28.369Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05451771", "title": "Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "Venetoclax Oral Tablet, 200 mg", "type": "DRUG" }, { "name": "FISH assay", "type": "DEVICE" }, { "name": "Venetoclax Oral Tablet, 400 mg", "type": "DRUG" }, { "name": "Dexamethasone Oral, 10 mg", "type": "DRUG" }, { "name": "Dexamethasone Oral, 20 mg", "type": "DRUG" }, { "name": "Daratumumab Injection", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Venetoclax MTD with Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2022-10-26", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05451771" }, { "nct_id": "NCT03012880", "title": "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-20", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012880" }, { "nct_id": "NCT02343042", "title": "Selinexor and Backbone Treatments of Multiple Myeloma Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Belantamab Mafodotin", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2015-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343042" }, { "nct_id": "NCT04047797", "title": "Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-08-28", "completion_date": "2025-04-11", "has_results": true, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047797" }, { "nct_id": "NCT02632396", "title": "Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2016-03-01", "completion_date": "2024-08", "has_results": false, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632396" }, { "nct_id": "NCT02302846", "title": "Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-03-20", "completion_date": "2017-05-30", "has_results": true, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302846" }, { "nct_id": "NCT01939899", "title": "Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "IXAZOMIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2013-10-31", "completion_date": "2017-03-23", "has_results": true, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01939899" }, { "nct_id": "NCT03213158", "title": "Ixazomib for Desensitization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Diseases", "End Stage Renal Disease" ], "interventions": [ { "name": "Ixazomib Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2017-09-15", "completion_date": "2021-04-16", "has_results": true, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213158" }, { "nct_id": "NCT03439293", "title": "A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2018-03-13", "completion_date": "2023-06-26", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 6, "location_summary": "Anaheim, California • Denver, Colorado • Tallahassee, Florida + 3 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439293" }, { "nct_id": "NCT02169791", "title": "Nonmyeloablative Haploidentical Transplant Followed by MLN9708", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Chronic Leukemia", "Myelodysplastic Syndrome", "Lymphomas", "Multiple Myeloma" ], "interventions": [ { "name": "MLN9708", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-07-15", "completion_date": "2020-07-28", "has_results": true, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-09-19T01:22:28.369Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169791" } ] }